UMD researchers have discovered key mechanisms in gene regulation that could improve the design of RNA-based medicines.

Klaus joins Epitopea after serving as Chief Development Officer (CDO) at Nykode Therapeutics, where he oversaw clinical development, regulatory affairs, and project management across oncology, ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

Announcing a new publication for Acta Materia Medica journal. Single-cell RNA sequencing (scRNA-seq) data from published datasets were obtained to investigate the expression and dysregulation of ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel ...

His research explores the rise of generative AI and accelerated use of AI more broadly to advance drug and scientific discovery. Reuben leads Gartner's coverage of genomics, multiomics, cell and gene ...

The platform enables direct, unbiased genome-wide identification and quantification of the exact position of double strand DNA breaks in edited cells.

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, ...

A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new mothers, and it has potential with other cancers as well.

While some of the initial zeal around localized vaccine production in Africa has waned since the height of the COVID-19 pandemic, efforts to bolster the continent’s immunization autonomy—especially | ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in licensing deals, on average, than in 2023 with an eye toward enriching their ...

Africa’s EVA Pharma, France’s DNA Script, and Belgium’s Quantoom Biosciences have signed a Memorandum of Understanding which ...